xanderla implantaat süstlis
teva b.v. - gosereliin - implantaat süstlis - 10,8mg 3tk; 10,8mg 2tk
reseligo implantaat süstlis
zentiva k.s. - gosereliin - implantaat süstlis - 10,8mg 1tk; 10,8mg 3tk
xanderla implantaat süstlis
teva b.v. - gosereliin - implantaat süstlis - 3,6mg 2tk; 3,6mg 3tk
nexplanon implantaat
organon n.v. - etonogestreel - implantaat - 68mg 5tk; 68mg 1tk
reseligo implantaat süstlis
zentiva k.s. - gosereliin - implantaat süstlis - 3,6mg 3tk
esperal impl.tabl. 100mg n10 implantaat
sanofi winthrop - disulfiraam - implantaat - 100mg 10tk
disulfiram implantaat
warsaw pharmaceutical works polfa s.a. - disulfiraam - implantaat - 100mg 10tk
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).